Hao HU 胡豪

• Researchgate: https://www.researchgate.net/profile/Hao_Hu11
• Google Scholar: https://scholar.google.com/citations?user=vQp5OVYAAAAJ&hl=zh-CN&oi=sra

Selected Publications (corresponding or first authorship)

1. Ruan Z^#, Chen X^#, Song M, Jia R, Luo H, Ung COL, Hu H*. Real-world utilization and effectiveness of glucagon-like peptide-1 receptor agonists dosed weekly and daily in patients with type 2 diabetes mellitus: results from retrospective electronic medical records in China. Diabetes, Metabolic Syndrome and Obesity, 2024;17: 3657–3666.
2. Lei PK^#, Liu Z^#, Ung COL, Hu H*. Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: a systematic review and meta-analysis. BMC Gastroenterology. 2024; 24: 331.
3. Zou H, Ge Y, Chen W, Yao D, Ung CO, Lai Y*, Hu H*. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors. International Immunopharmacology. 2024;132:111947.
4. Ge Y, Yao D, Ung COL, Xue Y, Li M, Lin J, Hu H*, Lai Y*. Digital medical information services delivered by pharmaceutical companies via WeChat: qualitative analytical study. Journal of Medical Internet Research. 2023;25:e43812.
5. Zou H, Xue Y, Chen X, Lai Y, Yao D, Ung COL, Hu H*. Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma. PLOS ONE. 2023; 18(10): e0292239.
6. Xue Y, Zou H, Ruan Z, Chen X, Lai Y, Yao D, Ung COL*, Hu H*. Pharmacoeconomic evaluation of anti-obesity drugs for chronic weight management: a systematic review of literature. Frontiers in Endocrinology. 2023;14:1254398.
7. Chen X, Shi J, Lai Y, Xue Y, Ung COL*, Hu H*. Systematic analysis of randomised controlled trials of Chinese herb medicine for non-alcoholic steatohepatitis (NASH): implications for future drug development and trial design. Chinese Medicine. 2023;18:58.
8. Ruan Z, Jiang Y, Shi H, Jia R, Ung COL, Hu H*. Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review. Expert Review of Clinical Pharmacology. 2023; 16(2): 161-176.
9. Xue Y, Ruan Z, Ung, COL, Lai Y, & Hu H*. Policy analysis of system responses to addressing and reversing the obesity trend in China: a documentary research. BMC Public Health. 2023; 23(1): 1198.
10. Yan X, Zou H, Lai Y, Ung CO, Hu H*. Efficacy and safety of first-line targeted treatment and immunotherapy for patients with biliary tract cancer: a systematic review and meta-analysis. Cancers. 2023;15(1):39.
11. Zou H, Lei Q, Yan X, Lai Y, Ung CO, Hu H*. Clinical outcomes associated with monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for advanced hepatocellular carcinoma in real-world practice: a systematic literature review and meta-analysis. Cancers. 2023;15(1):260.
12. Lei Q, Yan X, Zou H, Jiang Y, Lai Y, Ung CO, Hu H*. Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis. Discover Oncology. 2022;13(1):95.
13. Hu H*, Su J, Ma J. Smart hospital innovation: technology, service, and policy. Frontiers in Public Health. 2022;10:845577.
14. Lai Y, Wang R, Li W, Zhu H, Fei S, Shi H, Lu N, Ung COL, Hu H*, Han S*. Clinical and economic analysis of Gastrodin injection for dizziness or vertigo: a retrospective cohort study based on electronic health records in China. Chinese Medicine. 2022;17: 6.
15. Lin Q, Xue Y, Zou H, Ruan Z, Ung CO, Hu H*. Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials. Expert Review of Clinical Pharmacology. 2022;15(12):1461-9.
16. Liu L, Ruan Z, Ung CO, Zhang Y, Shen Y, Han S, Jia R, Qiao J, Hu H*, Guo L*. Long-term cost-effectiveness of subcutaneous once-weekly semaglutide versus polyethylene glycol loxenatide for treatment of type 2 diabetes mellitus in China. Diabetes Therapy. 2022; 14(1):93-107.
17. Ruan Z, Zou H, Lei Q, Ung COL, Shi H, Hu H*. Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research. 2022; 22(4): 555-574.
18. Ruan Z, Ung CO, Shen Y, Zhang Y, Wang W, Luo J, Zou H, Xue Y, Wang Y, Hu H*, Guo L*. Long-term cost-effectiveness analysis of once-weekly semaglutide versus dulaglutide in patients with type 2 diabetes with inadequate glycemic control in China. Diabetes Therapy. 2022; 13:1737-1753.
19. Xia C, Yao D, Lai Y, Xue Y, Hu H*. Market access of Chinese patent medicine products to healthcare security system in China: implications for international integration of traditional medicine into health systems. Chinese Medicine. 2022;17:5.
20. Zou H, Ge Y, Lei Q, Ung CO, Ruan Z, Lai Y, Yao D, Hu H*. Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review. Hepatology International. 2022; 16:27–37.
21. Zou H, Li M, Lei Q, Luo Z, Xue Y, Yao D, Lai Y, Ung COL*, Hu H*. Economic burden and quality of life of hepatocellular carcinoma in greater China: a systematic review. Frontiers in Public Health. 2022;21:767.
22. Lai Y, Chen S, Li M, Ung CO, Hu H*. Policy interventions, development trends, and service innovations of internet hospitals in China: documentary analysis and qualitative interview study. Journal of Medical Internet Research. 2021;23(7): e22330.
23. Li M, Cheng K, Ku K, Li J, Hu H*, Ung COL*. Factors influencing the length of hospital stay among patients with chronic obstructive pulmonary disease (COPD) in macao population: a retrospective study of inpatient health record. International Journal of Chronic Obstructive Pulmonary Disease. 2021;16:1677.
24. Li M, Chen S, Lai Y, Liang Z, Wang J, Shi J, Lin H, Yao D, Hu H*, Ung CO*. Integrating real-world evidence in the regulatory decision-making process: a systematic analysis of experiences in the US, EU, and China using a logic model. Frontiers in Medicine. 2021; 8:778.
25. Li M, Chen S, Zhao H, Tang C, Lai Y, Ung CO, Su J*, Hu H*. The short-term associations of chronic obstructive pulmonary disease hospitalizations with meteorological factors and air pollutants in Southwest China: a time-series study. Scientific Reports. 2021;11:12914.
26. Ruan Z, Yang L, Shi H, Yue X, Wang Y, Liang M, Hu H*. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 diabetes: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research. 2021, 21(2):221-233.
27. Salem A, Zhong H, Ramos M, Lamotte M, Hu H*. Potential clinical and economic impact of optimised maintenance therapy on discharged patients with COPD after hospitalisation for an exacerbation in China. BMJ open. 2021;11(4):e043664.
28. Shi H, Chen X, Liu X, Zhu H, Yu F, Ung CO, Chan WS, Hu H*, Han S*. National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018. Journal of Pharmaceutical Policy and Practice. 2021; 14:45.
29. Chen LX, Lai YF, Zhang WX, Cai J, Hu H^*, Wang Y, Zhao J*, Li SP*. Comparison of volatile compounds in different parts of fresh Amomum villosum Lour. from different geographical areas using cryogenic grinding combined HS–SPME–GC–MS. Chinese Medicine. 2020; 15: 97.
30. Cheong ST, Li J, Ung CO, Tang D, Hu H*. Building an innovation system of medical devices in China: Drivers, barriers, and strategies for sustainability. SAGE open medicine. 2020; 8: 1-14.
31. Hu Y, Yao D, Ung CO, Hu H*. Promoting community pharmacy practice for chronic obstructive pulmonary disease (COPD) management: a systematic review and logic model. International Journal of Chronic Obstructive Pulmonary Disease. 2020;15:1863.
32. Pang NI, Bie R, Ung CO, Hu H*. Development and validation of a logic model for utilization of nutrition support among patients with cancer. BioMed Research International. 2020; 2020: 4513719.
33. Yang L, Chen X, Oi Lam Ung C, Zhu H, Hu H*, Han S*. Clinical and economic evaluation of salvianolate injection for coronary heart disease: A Retrospective Study Based on National Health Insurance Data in China. Pharmacol. 2020; 11: 887.
34. Yao D, Hu Y, Harnett JE, Hu H*, Ung COL*. Community pharmacist’s perceptions and practice behaviors related to traditional and complementary medicines in China: a cross-sectional study. European Journal of Integrative Medicine. 2020; 40: 101225.
35. Zhang W, Ung COL, Lin G, Liu J, Li W, Hu H*, Xi X*. Factors contributing to patients’ preferences for primary health care institutions in China: a qualitative study. Front. Public Health 2020, 8:414
36. Chen S, Bie R, Lai Y, Shi H, Ung COL, Hu H*. Trends and development in enteral nutrition application for ventilator associated pneumonia: a scientometric research (1996-2018). Frontiers in Pharmacology. 2019; 10:
37. Shi H, Guo W, Zhu H, Li M, Ung COL, Hu H*, Han S. Cost-effectiveness analysis of Xiyanping Injection (Andrographolide Sulfonate) for treatment of adult community acquired pneumonia: a retrospective, propensity score-matched cohort study. Evidence-Based Complementary and Alternative Medicine. 2019; 2019: 4510591.
38. Song Q, Ung COL, Tang D, Hu H*. The use of microblog “Weibo” by Chinese Patent Medicine companies in China. Therapeutic Innovation & Regulatory Science, 2019; 53(4): 460-469. (SCI)
39. Tang D, Choi WI, Deng L, Bian Y, Hu H*. Health status of children left behind in rural areas of Sichuan Province of China: a cross-sectional study. BMC International Health and Human Rights. 2019; 19: 4.
40. Tang D, Li M, Ung COL, Tang C, Hu H*. Exploratory study on development challenges of maternal and child healthcare institutions in China: a qualitative study combining interviews and focus groups. BMJ Open. 2019; 9(6): e028789.
41. Xi X, Huang Y, Lu Q, Ung COL, Hu H*. Community pharmacists’ opinions and practice of pharmaceutical care at chain pharmacy and independent pharmacy in China. International Journal of Clinical Pharmacy. 2019; 41: 478-487.
42. Chen H, Ung CO, Chi P, Wu J, Tang D, Hu H*. Consumers’ perceptions about pharmaceutical care provided by community pharmacists in China in relation to over-the-counter drugs: a qualitative study. Inquiry. 2018; 55: 0046958018793292.
43. Choi WI, Shi H, Bian Y, Hu H*. Development of commercial health insurance in China: a systematic literature review. BioMed Research International. 2018; 2018: 3163746.
44. Chung CC, Hu H*. Divergent trajectories of sectoral evolution: the case of Traditional Chinese Medicine in China (1949–2015). Technological Forecasting and Social Change. 2018; 128: 252-261.
45. Dong P^†, Hu H^†, Guan X, Ung CO, Shi L, Han S, Yu S. Cost-consequence analysis of salvianolate injection for the treatment of coronary heart disease. Chinese Medicine. 2018; 13(1): 28.
46. Lai Y, Suo S, Wang R, Kong X, Hu Y, Tang D, Shi H, Chen S, Hu H*. Trends involving monoclonal antibody (mAb) research and commercialization: a scientometric analysis of IMS Lifecycle R&D Focus Database (1980–2016). Human Vaccines & Immunotherapeutics. 2018; 14(4): 847-855.
47. Li M, Wang F, Chen R, Liang Z, Zhou Y, Yang Y, Chen S, Ung COL*, Hu H*. Factors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record data. International Journal of Chronic Obstructive Pulmonary Disease. 2018; 13: 3349-3357.
48. Lin AX, Chan G, Hu Y, Ouyang D, Ung COL, Shi L, Hu H*. Internationalization of traditional Chinese medicine: current international market, internalization challenges and prospective suggestions. Chinese Medicine. 2018; 13(1): 9.
49. Suo S, Lai Y, Li M, Song Q, Cai J, Zhao J, Yang Q, Ung CO, Hu H*. Phytochemicals, pharmacology, clinical application, patents, and products of Amomi fructus. Food and Chemical Toxicology. 2018; 119: 31-36.
50. Ung COL, Harnett J, Hu H*. Development of a strategic model for integrating complementary medicines into professional pharmacy practice. Research in Social and Administrative Pharmacy. 2018; 14(7): 663-672.
51. Cai Y, Li P, Li XW, Zhao J, Chen H, Yang Q, Hu H*. Converting Panax ginseng DNA and chemical fingerprints into two-dimensional barcode. Journal of Ginseng Resesarch. 2017; 41(3): 339-346.
52. Lai Y, Wang R, Chen X, Tang D, Hu Y, Cai J, Zhang Q, Hu H*. Emerging trends and new developments in monoclonal antibodies: a scientometric analysis (1980–2016). Human Vaccines & Immunotherapeutics. 2017; 13(6): 1388-1397.
53. Song M, Ung COL, Lee VWY, Hu Y, Zhao J, Li P, Hu H*. Community pharmacists’ perceptions about pharmaceutical service of over-the-counter traditional Chinese medicine: a survey study in Harbin SCI of China. BMC Complementary and Alternative Medicine. 2017; 17(1): 9.
54. Ung COL, Harnett J, Hu H*. Community pharmacist’s responsibilities with regards to Traditional Medicine/Complementary Medicine products: a systematic literature review. Research in Social and Administrative Pharmacy, 2017; 13(4): 686-716.
55. Ung COL, Harnett J, Hu H*. Key stakeholder perspectives on the barriers and solutions to pharmacy practice towards complementary medicines: an Australian experience. BMC Complementary and Alternative Medicine. 2017; 17(1): 394.
56. Wang, L., Suo, S., Li, J., Hu, Y., Li, P., Wang, Y., & Hu, H*. An investigation into traditional Chinese medicine hospitals in China: development trend and medical service innovation. International Journal of Health Policy and Management, (2017). 6(1), 19.
57. Cai Y, Li X, Wang R, Yang Q, Li P, Hu H*. Quality traceability system of traditional Chinese medicine based on two dimensional barcode using mobile intelligent technology. PloS one.2016; 11(10): e0165263.
58. Chao CK, Hu H*, Zhang L, Wu J. Managing the challenges of pharmaceutical patent expiry: a case study of Lipitor. Journal of Science and Technology Policy Management. 2016; 7(3): 258-272.
59. Chen X, Ung COL, Hu H*, Liu X, Zhao J, Hu Y, Li P, Yang Q. Community pharmacists’ perceptions about pharmaceutical care of traditional medicine products: a questionnaire-based cross-sectional study in Guangzhou, China. Evidence-Based Complementary and Alternative Medicine: 2016; 2016: 7801637.
60. Hafsi T, Hu H*. Sectoral innovation through competing logics: the case of antidepressants in traditional Chinese medicine. Technological Forecasting and Social Change. 2016; 107:80-89.
61. Hu H, Wu J, Shi J. Strategic HRM and organisational learning in the Chinese private sector during second-pioneering. International Journal of Human Resource Management. 2016; 27(16): 1813-1832.
62. Lai YF, Chen LX, Chen YN, Zhao J, Leong F, Li XW, Yang Q, Li P, Hu H*. Sustainable development of Amomum Villosum: A systematic investigation on three production modes. African Journal of Traditional, Complementary & Alternative Medicines, 2016; 13(4): 97-104.
63. Song M, Guo H, Chen H, Hu H*. Characteristics of anti-cancer drug studies registered on the Chinese Clinical Trial Registry (ChiCTR) from 2007 to 2015. Journal of Evidence-Based Medicine. 2016; 9(2): 59-68.
64. Ung COL, Chao CK, Hu Y, Zhao J, Li P, Wang Y, Hu H*. Community pharmacists’ understanding, attitudes, practice and perceived barriers related to providing pharmaceutical care: a questionnaire survey in Macao. Tropical Journal of Pharmaceutical Research. 2016;15(4): 847-854. (SCI)
65. Cai Y, Li X, Li M, Chen X, Hu H*, Ni J, Wang Y. Traceability and quality control in traditional Chinese medicine: from chemical fingerprint to two-dimensional barcode. Evidence-Based Complementary and Alternative Medicine.2015; 2015: 251304. (SCI)
66. He TT, Hu H*, Wang YT. Implementation status and barriers of good manufacturing practice (GMP) for Chinese patent medicine. African Journal of Traditional, Complementary and Alternative Medicines. 2015; 12(4): 56-64.
67. He TT, Ung COL, Hu H*, Wang YT. Good manufacturing practice (GMP) regulation of herbal medicine in comparative research: China GMP, cGMP, WHO-GMP, PIC/S and EU-GMP. European Journal of Integrative Medicine. 2015; 7(1): 55–66.
68. Hu H, Chung CC*. The innovation and modernisation of ‘herbal pieces’ in China: System evolution and policy transitions (1950s–2010s). European Journal of Integrative Medicine. 2015; 7(6): 645-649.
69. Hu H, Chung CC.* Biopharmaceutical innovation system in China: system evolution and policy transitions (Pre-1990s-2010s). International Journal of Health Policy and Management. 2015; 4(12): 823-829.
70. Hu H, Hafsi T. Entrepreneurial social capital and reciprocal dependence effects on strategy: An empirical study of CROs in China. International Journal of Entrepreneurship and Small Business. 2015; 24(2): 208-232.
71. Hu H*, Zhang LM. Catch-Up of Chinese pharmaceutical firms facing technological complexity. International Journal of Innovation and Technology Management. 2015; 12(4): 1550017.
72. Lai YF, Lu JJ, Hu H*, Wang YT. Analysis of the current situation of antitumor drug use in China: a hospital-based perspective. Therapeutic Innovation & Regulatory Science. 2015; 49(1): 181-193. (SCI)
73. Li XW, Chen YN, Lai YF, Yang Q,* Hu H*, Wang YT. Sustainable utilization of traditional Chinese medicine resources: systematic evaluation on different production modes. Evidence-Based Complementary and Alternative Medicine. 2015; 2015: 218901. (SCI)
74. Song M, Ung COL, Hu H*, Wang Y. Community pharmacists’ perceptions about pharmaceutical care of OTC western medicine: a survey in Harbin of China. International Journal of Clinical Pharmacy. 2015; 37(6): 1014-1020. (SCI)
75. Yu XW, Hu H*, Chen XP, Hu Y, Wang YT. Technology road mapping for innovation pathways of fibrates: a cross-database patent review. Tropical Journal of Pharmaceutical Research. 2015; 14(8): 1459-1467. (SCI)
76. Zhang MY, Li J, Hu H*, Wang Y. Seizing the strategic opportunities of emerging technologies by building up innovation system: monoclonal antibody (mAb) development in China. Health Research Policy and System. 2015; 13:64. (SSCI)
77. Zhang MY, Lu JJ, Wang L, Gao ZC, Hu H*, Ung COL, Wang YT. Development of monoclonal antibodies in China: overview and prospects. BioMed Research International. 2015; 2015: 168935. (SCI)
78. Duan GM, Qiu L, Yu WP, Hu H*. Outpatient service quality and doctor-patient relationship: a study in Chinese public hospital. International Journal of Services, Economics and Management. 2014; 6(1): 97-111.
79. Ge S, He TT, Hu H*. Popularity and customer preferences for over-the-counter Chinese medicines perceived by community pharmacists in Shanghai and Guangzhou: a questionnaire survey study. Chinese Medicine. 2014; 9: 22. (SCI)
80. Ma ZQ, Hu H*, Zhang MY, He TT, Guo H, Chen MW, Wang YT. An assessment of traditional Uighur medicine in current Xinjiang region (China). African Journal of Traditional, Complementary and Alternative Medicines. 2014; 11(2): 301-314. (SCI).
81. He TT, Hu H*, Wang YT. From low tech to modern industry: a study of traditional Chinese medicine sector in Guangdong, China. Journal of Science & Technology Policy Management. 2014; 5(3): 247-264.
82. Ng W, Hu H*. From medicine to food: evolution of TCM health food sector in China. International Journal of Transitions and Innovation Systems. 2014; 3(4): 291-306.
83. Qiu L, Chen ZY, Lu DY, Hu H*, Wang YT. Public funding and private investment for R&D: a survey in China’s pharmaceutical industry. Health Research Policy and Systems. 2014; 12: 27. (SSCI)
84. Qiu L, Yu YY, Liu JJ, Hu H*, Wang YT. For-profit medical institutions in China: current status analysis and comparation with non-profit ones. Journal of Pharmaceutical and Health Services Research. 2014; 5(1): 37-47.
85. Shi YZ, Hu H*, Wang C. Contract Research Organizations (CROs) in China: integrating Chinese research and development capabilities for global drug innovation. Globalization and Health. 2014; 10: 78. (SSCI)
86. Shi YZ, Hu H*, Wang YT. Technology uncertainty and technology sourcing: case study of biopharmaceuticals in China. International Journal of Business Innovation and Research. 2014; 8(5): 566-580.
87. Yu WP, Chen Y, Duan GM, Hu H*, Ma HS, Dai Y. Patients’ perceptions of day surgery: a survey study in China. Hong Kong Medical Journal. 2014; 20(2): 134-138. (SCI)
88. Yu YY, Ma ZQ, Hu H*, Wang YT. Local government policies and pharmaceutical clusters in China. Journal of Science and Technology Policy Management. 2014; 5(1): 41-58.
89. Zhang MY, Chong WK, Hu H*, Wang YT. Pharmacy-perceived consumer preferences: a survey of community pharmacies in Macau. Journal of Medical Marketing. 2014; 14(1): 41–48.
90. Chao WC, Hu H*, Ung COL, Cai Y. Benefits and challenges of electronic health record system on stakeholders: a qualitative study of outpatient physicians. Journal of Medical Systems. 2013; 37(4): 9960.
91. Chong WK, Chao WC, Hu H*, Cheng LJ. Responses of community pharmacies to rapidly rising competition: a survey study in Macao. International Journal of Pharmaceutical Science and Health Care. 2013; 3(3): 1-8.
92. Io UM, Hu H*, Ung COL. Physicians’ and pharmacists’ experience and expectations of the roles of pharmacists: insights into hospital setting in Macao. Tropical Journal of Pharmaceutical Research. 2013; 12(6): 1077-1085.
93. Shi HH, Chen MW, Shi YZ, Hu H*, Wang YT. Challenges and prospects for monoclonal antibodies in China. Journal of Commercial Biotechnology. 2013; 19(2): 48-54.
94. Yu WP, Yu XW, Hu H*, Duan GM, Liu Z, Wang YT. Use of hospital appointment registration systems in China: a survey study. Global Journal of Health Science. 2013; 5(5): 193-201.
95. Zhang N, Liu JJ, Hu H*, Wang YT. Cultural consideration in branding strategy of Chinese Patent Medicine: field study in Singapore, Guangzhou and Hong Kong. Journal of Medical Marketing. 2013; 13(3): 160-170.
96. Zhang LM, Lam WO, Hu H*. Complex product and system, catch-up, and sectoral system of innovation: a case study of leading medical device companies in China. International Journal of Technological Learning, Innovation and Development. 2013; 6(3): 283-302.
97. Zhao HY, Hu H*, Wang YT. Comparative metabolism and stability of andrographolide in liver microsomes from humans, dogs and rats using ultraperformance liquid chromatography coupled with triplequadrupole and Fourier transform ion cyclotron resonance mass spectrometry. Rapid Communication in Mass Spectromery. 2013; 27(12): 1385-1392. (SCI)
98. Lai YF, Lu JJ, Chen XP, Hu H*, Wang YT. Analysis of anti-cancer traditional Chinese Medicine Injections based on market performance. World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica. 2012; 14(5): 1958-1962.

1. Leung SW, Hu H. 2016. Evidence-based Research Methods for Chinese Medicine. Springer.
2. Hu H, Zhang LM. 2014. Rebuild Value Logics: Business Model Innovation in the Chinese Pharmaceutical Industry. Beijing: Tsinghua University Press. (In Chinese)